Latest Breaking News On - Panacea biotech - Page 15 : comparemela.com

India will receive the first batch of Sputnik V COVID-19 vaccine by May 1 — in time for the third phase of its vaccination drive

India will receive the first batch of Sputnik V COVID-19 vaccine by May 1 — in time for the third phase of its vaccination drive
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

Sri lankaKirill dmitrievStelis biopharmaMoscow gamaleya national research institute of epidemiologySerum institute of indiaRussian direct investment fundWorld health organisationGamaleya national research instituteSerum instituteBharat biotechDrug controller generalHetero biopharmaGland pharmaPanacea biotechVirchow biotechBusiness insider

Sensex slips 202 points, ends below 48K

Sensex slips 202 points, ends below 48K
sentinelassam.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sentinelassam.com Daily Mail and Mail on Sunday newspapers.

Bharti airtelDeeplina deka bihuDr reddy labsConfidence petroleum indiaIndian bankIndian hotelPower gridCoal indiaPanacea biotechMuthoot financeSouth koreaSinger deeplina dekaBihu function cancelled amidபாரதி ஏர்டெல்டாக்டர் சிவப்பு ஆய்வகங்கள்நம்பிக்கை பெட்ரோலியம் இந்தியா

Johnson & Johnson s Covid vaccine expected to be imported by June-July: Science and technology ministry | India News

NEW DELHI: Johnson & Johnson s single-shot coronavirus vaccine is expected to be imported to India for fill and finish by June or July this year, said Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology on Thursday. The Johnson & Johnson s vaccines are expected to be imported to India by June-July 2021. Johnson & Johnson s is working closely with Biological E to facilitate the ongoing tech transfer to India, Swarup told ANI. Talking about the vaccine, Swarup said that Johnson & Johnson s vaccine candidate leverages the adenovirus vector-based delivery system. To expand the manufacturing capacity in India, Johnson & Johnson has signed a tech-transfer agreement with Biological E Limited, for the manufacturing of their investigational single dose, SARS-CoV-2 vaccine candidate, Ad26.COV2.S. This would add to the manufacturing capacity of India, she said.

Bala venkatesh varmaOxford covidRenu swarupStelis biopharmaSerum institute of indiaRussian direct investment fundDepartment of biotechnologyMinistry of scienceBiologicale limitedNew england journalEmergency use authorisationHetero biopharmaVirchow biotechGland biopharmaPanacea biotechIndian ambassador

Hyderabad s Biological E set to give fourth vaccine for India

Hyderabad’s Biological E set to give fourth vaccine for India By M Somasekhar| Updated: 23rd April 2021 9:13 pm IST M Somasekhar Hyderabad: Biological E, the country’s first manufacturer of vaccines in the private sector is all set to launch India’s fourth vaccine against COVID 19 by August 2021. According to the Indian Council of Medical Research( ICMR) , Biological E is testing a two-dose vaccine similar to ‘Covaxin’, made by Bharat Biotech, another Hyderabad -based, vaccine maker. The Niti Aayog member (health) Dr V K Paul recently said, “Biological E has finished phase-1/2 trials. They are submitting the data in the next few days after which they will initiate phase-3 trials of the vaccine.”

Andhra pradeshUnited statesBaylor college of medicineHimachala pradeshSanofi shanthaZydus cadilaMahima datlaHester biosciencesGamelaya research institute of epidemiologyProsperity initiativeWorld health organization emergency use listingAstra institute of indiaIndian council of medical researchWorld bankCooperation agencyCoalition for epidemic preparedness innovations

Panacea Biotech stock hits over 12-year high; zooms 83% thus far in April

Shares of Panacea Biotech were locked in the 10 per cent upper circuit for the second straight day, at Rs 323.70, hitting an over 12-year high on the BSE on Thursday. The stock of the biotechnology company was trading at its highest level since August 2008. It had hit a record high of Rs 487 on April 21, 2006. Thus far in the month of April, the market price of Panacea Biotech has zoomed 83 per cent after the company and the Russian Direct Investment Fund (RDIF) agreed to produce 100 million doses of Sputnik V vaccine in India per year. In comparison, the S&P BSE Sensex has slipped 4.4 per cent so far in the current month.

Serum institute of india privateRussian direct investment fundPanacea biotechPanacea biotecIndia private limitedPanacea biotech share priceசீரம் நிறுவனம் ஆஃப் இந்தியா ப்ரைவேட்ரஷ்ய நேரடி முதலீடு நிதிசஞ்சீவி பயோடெக்இந்தியா ப்ரைவேட் வரையறுக்கப்பட்டவை